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Community-
acquired 
Oseltamivir-
Resistant Pandemic
 (H1N1) 2009 in 
Child, Israel
To the Editor: During the spring 
of 2009, a pandemic inﬂ  uenza  A 
(H1N1) virus emerged and spread 
globally. Initial testing of the virus 
found it susceptible to neuraminidase 
inhibitors and resistant to adamantanes 
(1,2). As of March 5, 2010, only 264 
cases of oseltamivir-resistant pandem-
ic (H1N1) 2009 infection had been re-
ported to the World Health Organiza-
tion, but the number of cases has been 
steadily increasing (2). These viruses 
were carrying the H275Y mutation, 
which conferred resistance to oselta-
mivir (2). Most of the reported cases 
were in immunocompromised patients 
who had prolonged viral shedding or 
in patients who had received oseltami-
vir prophylaxis or treatment (1–4). We 
describe an otherwise healthy 2-year-
old boy with oseltamivir-resistant pan-
demic (H1N1) 2009 infection and a 
traumatic lung contusion, complicated 
by acute respiratory distress syndrome 
(ARDS). He had not received prior 
chemoprophylaxis or treatment with 
oseltamivir.
In November 2009, a healthy 
2-year-old boy was admitted to the 
pediatric intensive care unit at the 
Western Galilee Hospital in Nahariya, 
Israel, after he had been hit by a car. 
One day before the accident, he had 
exhibited fever and cough (for which 
he was treated with acetaminophen). 
His 4-year-old brother had recovered 
recently from an inﬂ  uenza-like illness 
without antiviral treatment. The other 
household contacts were his parents, 
who did not have a respiratory illness.
On admission, small, bilateral 
lung contusions, right pneumothorax, 
and liver lacerations were shown on 
computed tomographic scan. The pa-
tient was treated with a chest tube for 
drainage, supplemental oxygen, and 
oseltamivir from hospital day 1 (30 
mg 2 ×/day; child’s body weight = 13 
kg) and was placed in droplet isola-
tion. Respiratory swab specimens, ob-
tained on hospital day 1, were sent to 
the Israel Central Virology Laboratory 
(ICVL) and found to be positive for 
pandemic (H1N1) 2009 by real-time 
reverse transcription–PCR (RT-PCR). 
On hospital day 3, the child was intu-
bated because of worsening respira-
tory distress and hypoxemia, and he 
required a second chest tube drain. 
His chest ﬁ  lm showed bilateral pulmo-
nary inﬁ  ltrates. His condition was then 
treated with nitric oxide, dopamine, 
and milrinone for ARDS and failure of 
the right side of the heart. The dosage 
of oseltamivir was doubled on hospi-
tal day 4 because of gastric residuals. 
Antimicrobial drug therapy with van-
comycin and piperacillin-tazobactam 
was added because sepsis and sec-
ondary bacterial lung infection were 
suspected. Because of the severity of 
his symptoms and persistence of fe-
ver, additional lower and upper airway 
specimens were sent to ICVL on hos-
pital days 5 and 10; they were positive 
for pandemic (H1N1) 2009.
After these results were received, 
oseltamivir resistance was suspected, 
and his respiratory specimens were 
also checked by ICVL. A mixture of 
both wild-type and mutant pandemic 
(H1N1) 2009 was found in the speci-
mens from hospital days 1, 5, and 10 
by an in-house q-RT-PCR assay de-
signed to detect the H275Y mutation 
(4,5). Further testing by sequence 
analysis of the neuraminidase gene 
showed a mixed population of wild-
type and mutant  pandemic (H1N1) 
2009; the mutant virus was carrying 
the histidine-to-tyrosine substitution 
at position 275, which conferred the 
quantitative RT-PCR result and the 
H275Y phenotype of oseltamivir-
resistant pandemic (H1N1) 2009. By 
the time these laboratory results were 
known, the patient’s respiratory con-
dition was improving without chang-
ing the oseltamivir therapy. Cultures 
of blood and endotracheal specimens 
were sterile and antimicrobial drug 
therapy was stopped. On hospital day 
15, he was extubated, oseltamivir ther-
apy was ended, and he was weaned off 
oxygen a few days later. The respira-
tory specimen on hospital day 20 was 
negative for pandemic (H1N1) 2009. 
No secondary inﬂ  uenza cases were de-
tected among healthcare personnel or 
patients in the unit.
In Israel, oseltamivir resistance 
has been detected by ICVL in 6 cases 
(5). The fact that our patient had os-
eltamivir-resistant pandemic (H1N1) 
2009 without a previous oseltamivir 
exposure is surprising because almost 
all cases of oseltamivir-resistance 
have been associated with previous 
oseltamivir prophylaxis or therapy and 
with prolonged viral shedding (which 
is often combined with oseltamivir 
therapy) in immunocompromised pa-
tients (1–5). Our patient did not at-
tend daycare and his parents had not 
been ill recently. Therefore, he likely 
was infected by his older brother who 
probably had pandemic (H1N1) 2009 
but was neither diagnosed nor treated 
with antiviral medications. This theory 
suggests that oseltamivir-resistant vi-
ruses circulate in the community with 
the potential to be transmitted between 
persons. 
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Lung contusions and pandemic 
(H1N1) 2009 can cause ARDS (6,7). 
We do not know the relative role of 
each in causing the ARDS that our pa-
tient had, but the severity of clinical 
symptoms, although the lung injury 
was judged to be only of moderate 
magnitude, suggests that inﬂ  uenza 
played a major role in the develop-
ment of his acute lung disease. The 
infection with oseltamivir-resistant 
virus, for which he probably did not 
receive effective therapy, likely had an 
effect on the duration and severity of 
his course. 
Although our patient had a fa-
vorable outcome, the possibility of 
widespread resistance, similar to the 
phenomenon observed with seasonal 
inﬂ  uenza in the 2008–2009 season, is 
alarming and should be monitored. The 
suspicion of resistance should be based 
upon compatible clinical scenario, such 
as continuation of symptoms in spite of 
antiviral therapy (even in patients who 
are not immunocompromised), com-
bined with early performance of resis-
tance assays. Early and rapid detection 
of oseltamivir resistance and a change 
of antiviral treatment (if feasible) might 
beneﬁ  t the patient. 
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Human Infection 
with Lymphocytic 
Choriomeningitis 
Virus
To the Editor: I read with great 
interest the article regarding lympho-
cytic choriomeningitis virus (LCMV) 
meningitis in a New York City resident 
(1). The authors’ conclusion that there 
is a need to ascertain the true incidence 
of LCMV infection is worthy of under-
scoring. Nearly 15 years ago, in this 
same journal, we described congenital 
LCMV as an unrecognized teratogen 
and recommended further “research 
to deﬁ   ne the frequency of LCMV” 
(2). Five years later, we reiterated that 
recommendation when reporting ac-
quired LCMV meningoencephalitis in 
an adolescent from Tucson, Arizona 
(3). Despite, or because of, the lack of 
prospective studies, the fact that this 
author has accrued data regarding >60 
congenitally infected infants from all 
geographic areas in the United States 
during the past 15 years reinforces 
the concept that LCMV is a neglected 
pathogen whose time for more exten-
sive study has indeed come.
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